Infektiologie Tirol, Department of Virology, 9931, Unterwalden 30, Außervillgraten, Austria.
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Nat Commun. 2022 May 10;13(1):2560. doi: 10.1038/s41467-022-30163-4.
Different scenarios explaining the emergence of novel variants of concern (VOC) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported, including their evolution in scarcely monitored populations, in animals as alternative hosts, or in immunocompromised individuals. Here we report SARS-CoV-2 immune escape mutations over a period of seven months in an immunocompromised patient with prolonged viral shedding. Signs of infection, viral shedding and mutation events are periodically analyzed using RT-PCR and next-generation sequencing based on naso-pharyngeal swabs, with the results complemented by immunological diagnostics to determine humoral and T cell immune responses. Throughout the infection course, 17 non-synonymous intra-host mutations are noted, with 15 (88.2%) having been previously described as prominent immune escape mutations (S:E484K, S:D950N, S:P681H, S:N501Y, S:del(9), N:S235F and S:H655Y) in VOCs. The high frequency of these non-synonymous mutations is consistent with multiple events of convergent evolution. Thus, our results suggest that specific mutations in the SARS-CoV-2 genome may represent positions with a fitness advantage, and may serve as targets in future vaccine and therapeutics development for COVID-19.
已报道了多种解释严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)新型关注变异株(VOC)出现的情况,包括在监测甚少的人群中、在动物作为替代宿主中或在免疫功能低下个体中发生的进化。在此,我们报告了一名免疫功能低下患者在病毒持续排出的情况下,7 个月内 SARS-CoV-2 免疫逃逸突变的情况。通过基于鼻咽拭子的 RT-PCR 和下一代测序定期分析感染、病毒排出和突变事件,结果通过免疫学诊断补充,以确定体液和 T 细胞免疫反应。在整个感染过程中,注意到 17 个非同义宿主内突变,其中 15 个(88.2%)之前被描述为突出的免疫逃逸突变(S:E484K、S:D950N、S:P681H、S:N501Y、S:del(9)、N:S235F 和 S:H655Y)在 VOC 中。这些非同义突变的高频率与多次趋同进化事件一致。因此,我们的结果表明,SARS-CoV-2 基因组中的特定突变可能代表具有适应性优势的位置,并可能成为未来 COVID-19 疫苗和治疗药物开发的靶点。